5-Bromo-2-(difluoromethyl)-1,3-difluorobenzene, 98.0%, 250mg

4-Phenylpiperidine-4-carbonitrile, 95.0%, 1g

((2R,7aS)-2-Fluorotetrahydro-1H-pyrrolizin-7a(5H)-yl)methanol, 95%, 1g

2-Amino-3-fluorobenzaldehyde, 95.0%, 100mg

1,5-Naphthalenedisulfonic acid tetrahydrate, 98.0%, 25g

(S)-2-((((9H-Fluoren-9-yl)methoxy)carbonyl)(methyl)amino)-2-cyclohexylacetic acid, 97%, 5g

(S)-3-Aminopiperidine-2-one, 97.0%, 1g

(R)-2-Amino-3-(4-(aminomethyl)phenyl)propanoic acid, 95.0%, 250mg

3-(4-tert-Butyl-2,6-dimethylphenyl)-2-methyl-1-propene, 97.0%, 1g

Glycine, N-[N-[(9H-fluoren-9-ylmethoxy)carbonyl]-L-valyl]-, 98%, 1g

butyl[(2-fluorophenyl)methyl]amine hydrochloride, 95.0%, 1g

Methyl 2-(4-methylphenylsulfonamido)acetate, 95.0%, 1g

Anti-alpha Gal Polyclonal Antibody R-PE Conjugate1vial